Evaluation and management of insomnia, muscle cramps, fatigue, and itching in cirrhotic patients
Christopher Moore – 29 January 2016
Review of current and potential future pharmacological treatments in nonalcoholic steatohepatitis
Ahmed Akhter, Abhishek Pulla, Adnan Said – 29 January 2016
Social determinants in liver transplantation
Joel T. Adler, Heidi Yeh – 29 January 2016
Reply
Vivek Vij – 29 January 2016
A score model for the continuous grading of early allograft dysfunction severity
Michel Rayar, Giovanni Battista Levi Sandri, Caterina Cusumano, Nicolas Lombard, Mohamed Lakehal, Veronique Desfourneaux, Bernard Meunier, Laurent Sulpice, Karim Boudjema – 29 January 2016
Broadening the implications of gene discovery
Eve A. Roberts – 28 January 2016
Targeting the Achilles' heel of adult living donor liver transplant: Corner‐sparing sutures with mucosal eversion technique of biliary anastomosis
Ming Li, Li Jiang, Lunan Yan, Jiayin Yang – 28 January 2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)
Vincent Leroy, Peter Angus, Jean‐Pierre Bronowicki, Gregory J. Dore, Christophe Hezode, Stephen Pianko, Stanislas Pol, Katherine Stuart, Edmund Tse, Fiona McPhee, Rafia Bhore, Maria Jesus Jimenez‐Exposito, Alexander J. Thompson – 28 January 2016 – Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of optimally effective therapies.
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)
Vincent Leroy, Peter Angus, Jean‐Pierre Bronowicki, Gregory J. Dore, Christophe Hezode, Stephen Pianko, Stanislas Pol, Katherine Stuart, Edmund Tse, Fiona McPhee, Rafia Bhore, Maria Jesus Jimenez‐Exposito, Alexander J. Thompson – 28 January 2016 – Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of optimally effective therapies.
The changing face of liver transplantation for acute liver failure: Assessment of current status and implications for future practice
Mhairi C. Donnelly, Peter C. Hayes, Kenneth J. Simpson – 28 January 2016 – The etiology and outcomes of acute liver failure (ALF) have changed since the definition of this disease entity in the 1970s. In particular, the role of emergency liver transplantation has evolved over time, with the development of prognostic scoring systems to facilitate listing of appropriate patients, and a better understanding of transplant benefit in patients with ALF.